platinum has been researched along with 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andresen, C; Bajorin, D; Burris, H; Daneshmand, S; De Giorgi, U; Galsky, M; Grivas, P; Gupta, S; Hoffman-Censits, J; Li, A; Lyou, Y; Moran, S; Pal, SK; Petrylak, D; Quinn, DI; Rearden, J; Rosenberg, JE; Vaishampayan, U; Xu, C | 1 |
1 other study(ies) available for platinum and 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea
| Article | Year |
|---|---|
Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma.
Topics: Carcinoma, Transitional Cell; Female; Humans; Male; Phenylurea Compounds; Platinum; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 3; Salvage Therapy; Urinary Bladder Neoplasms | 2022 |